Dementia Discovery Fund Acquires Small Molecule Library and Enters Strategic Partnership with Aptuit to Kickstart Dementia Drug Discovery Programmes

The Dementia Discovery Fund announces the acquisition of a >500,000 compound, CNS-biased small molecule library The DDF and Aptuit enter into a strategic partnership to leverage the DDF library and Aptuit’s capabilities for dementia drug discovery London, Boston, Greenwich - February 28, 2017 – The ...

Topics: Drug design and discovery, Hit Discovery, Drug Discovery, Dementia Drug Discovery, Computational Chemistry, Compound Logistics, Assay Development Read More

SAMDI Tech, Inc. and Aptuit Announce Drug Discovery Screening Partnership

CHICAGO, IL – February 7, 2017 – SAMDI Tech, Inc. and Aptuit, LLC are partnering to broaden their portfolio of assay development and high-throughput drug discovery services in Europe and North America. The partnership provides early-stage drug discovery researchers with access to SAMDI Tech’s ...

Topics: Strategy, Corporate, Business, Drug design and discovery Read More

Aptuit announces drug discovery collaboration with Massachusetts General Hospital (MGH) to identify novel treatments for Gram-negative infections

Greenwich, CT - January 24, 2017 - Aptuit, LLC today announced the start of a collaboration with the Molecular Surgical Laboratory of Massachusetts General Hospital (MGH), directed by Dr. Laurence Rahme, aimed at the identification and validation of novel targets in Gram-negative bacteria. Aptuit ...

Topics: Corporate, Drug design and discovery Read More

Chronos Therapeutics partners with Aptuit for addictive behaviour programmes

Oxford, UK - January 9, 2017 - Chronos Therapeutics Ltd (Chronos), the private biotech company focused on ageing diseases, brain and nervous system disorders, announced that they have partnered with a subsidiary of Aptuit Holdings LLC (Aptuit) for services related to Chronos’ programme targeting ...

Topics: Corporate, Business Read More

Aptuit and Chiesi Initiate Integrated Discovery Project to Identify Novel Compounds for the Treatment of Idiopathic Pulmonary Fibrosis

Greenwich, CT, and Parma, Italy – January 4, 2017 Aptuit, LLC, a premier global drug discovery and development CRO, and Chiesi Farmaceutici (Chiesi), an international research-focused Healthcare Group, announced today that they have entered an agreement under which Aptuit will conduct an integrated ...

Topics: Corporate, Business, Drug design and discovery Read More

Aptuit Announces Expansion of Compound Library

Part of 5m$ Investment in Integrated Drug Discovery Capabilities Greenwich, CT, November 30, 2016 - Aptuit, LLC today announced that it had successfully completed the expansion of their lead-like screening library. An additional 150,000 novel compounds have increased the Screening Collection to ...

Topics: Corporate, Business Read More

Aptuit names Peter Gray as the new Chairman of Aptuit Holdings, LLC

Greenwich, CT, November 28, 2016 – Aptuit today announced that Peter Gray has been appointed Chairman of Aptuit’s Board of Managers. Mr. Gray assumes the role of Chairman having previously served as Non-Executive Director since March 2015. Mr. Gray said, “I am honoured to assume the role of ...

Topics: Corporate Read More

Aptuit announces enhancement of integrated IND enabling services

Expanding capabilities and capacity in formulation development and safety assessment Greenwich, CT, October 13, 2016 - Aptuit, LLC today announced that it has relocated its recently acquired subsidiary Kuecept to its Oxford UK site, and added further formulation and safety assessment capacity to ...

Topics: Business Read More

Tim Tyson to leave as Chairman of Aptuit

Tim Tyson has resigned as Chairman to focus on other opportunities.  The company wishes him well for the future and thanks him for his many contributions.

Aptuit LLC and Dimension Therapeutics enter strategic partnership to advance select Dimension programs toward IND filing

Aptuit Greenwich, CT, and Cambridge, MA - July 7, 2016 – Aptuit LLC, a premier global drug discovery and development CRO, and Dimension Therapeutics, a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, ...

Topics: Strategy, Corporate, Business Read More